6,6-dimethyl-[1,4]diazepane | 67744-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: 6,6-dimethyl-[1,4]diazepane
• 英文别名: 6,6-Dimethyl-1,4-diazepane
• CAS: 67744-49-4
• 化学式: C₇H₁₆N₂
• mdl: MFCD08669934
• 分子量: 128.217
• InChiKey: MPEHMHGIZSYABM-UHFFFAOYSA-N

物化性质

• 熔点：
  59-60 °C
• 沸点：
  180-185 °C
• 密度：
  0.828±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyl 2-(chlorocarbonyl)-7-azaspiro[3.5]nonane-7-carboxylate 、 6,6-dimethyl-[1,4]diazepane 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 benzyl 2-(6,6-dimethyl-1,4-diazepane-1-carbonyl)-7-azaspiro[3.5]nonane-7-carboxylate
  参考文献：
  名称：

  Spirocyclobutyl Piperidine Derivatives

  摘要：

  披露至少一种螺环环丁基哌啶衍生物，至少一种包含本文披露的至少一种螺环环丁基哌啶衍生物的药物组合物，以及至少一种使用本文披露的至少一种螺环环丁基哌啶衍生物治疗至少一种组胺H3受体相关状况的方法。

  公开号：

  US20100130477A1
• 作为产物：
  描述：

  6.6-dimethylhexahydro-1.4-diazepin-2-one 、 氢化铝锂 以50%的产率得到
  参考文献：
  名称：

  MAJCHRZAK M.; KOTELKO A.; GURYN R., POL. J. CHEM., 1978, 52, NO 5, 1023-1028

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND THERAPEUTIC USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：VIOGEN BIOSCIENCES LLC

  公开号：WO2020243457A1

  公开（公告）日：2020-12-03

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia, viral infection including SARS-CoV-2, and other complications associated with the foregoing diseases and disorders.

  这项发明涉及化合物、药物组合物和方法，用于治疗癌症、全身性或慢性炎症、类风湿关节炎、糖尿病、肥胖症、T细胞介导的自身免疫疾病、与IL12/IL23过度产生相关的疾病、溶酶体贮积疾病、丝状病毒感染、缺血、包括阿尔茨海默病、肌萎缩侧索硬化和额颞叶痴呆症在内的神经退行性疾病、包括SARS-CoV-2的病毒感染，以及与上述疾病和疾病相关并发症。
• [EN] CAPTOPRIL DERIVATIVES<br/>[FR] DERIVES DE CAPTOPRIL
  申请人：NICOX SA

  公开号：WO2004106300A1

  公开（公告）日：2004-12-09

  Captopril nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment or prophylaxis of cardiovascular, inflammatory and renal diseases.

  Captopril的硝基衍生物具有改善的药理活性和增强的耐受性。它们可用于治疗或预防心血管、炎症和肾脏疾病。
• [EN] DIMERIC IAP INHIBITORS<br/>[FR] INHIBITEURS IAP DIMÉRIQUES
  申请人：NOVARTIS AG

  公开号：WO2012080271A1

  公开（公告）日：2012-06-21

  The present invention provides compounds of formula M-L-M' (where M and M' are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. (I)

  本发明提供了公式M-L-M'的化合物（其中M和M'分别独立地是公式（I）的单体基团，L是连接基团）。已发现二聚化合物在促进快速分裂细胞凋亡方面具有有效性。（I）
• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• Dihydrothienopyrimidines
  申请人：GERLACH Kia

  公开号：US20130196988A1

  公开（公告）日：2013-08-01

  The present invention relates to dihydrothienopyrimidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Aβ peptides.

  本发明涉及二氢噻吡嘧啶类化合物，其作为γ-分泌酶调节剂的用途，以及含有这些化合物的药物组合物。具体而言，本发明涉及干扰γ-分泌酶和/或其底物的化合物，从而调节Aβ肽的形成。